CONGRATULATIONS TO THOSE WHO FOLLOWED US ON ACTELION , $70+ ON 121ST BUYOUT, 289.76%+ ANNUALIZED RETURN, BUYER IS JOHNSON & JOHNSON $ALIOY $JNJ

CONGRATULATIONS TO THOSE WHO FOLLOWED US ON ACTELION , $70+ ON 121ST BUYOUT, 289.76%+ ANNUALIZED RETURN, BUYER IS JOHNSON & JOHNSON $ALIOY $JNJ

This post was just published on ZYX Buy Change Alert. 

Only 62 days ago our call was to buy ALIOY on a potential buyout.  Average price is $45.57.  This is the 121st buyout of our portfolio companies. Over the years, the long-time subscribers to The Arora Report have generated substantial wealth from so many of our portfolio companies getting bought out producing handsome profits.

The buyout by JNJ is for $70 cash plus the holders will get shares in a new company that will contain R&D efforts of Europe’s largest biotech.

The 289.76% annualized return  is calculated on $68 per share where the stock is trading as of this writing and not on $70 per share.  Of course you will get $70 cash when you tender the shares.  Your actual return is higher because you will also get shares in the new R&D company in which your cost basis will be zero and what ever price it trades at will be pure profit.  We expect the transaction to close in June.

What To Do Now

Those in the stock may continue to hold and tender their shares.

Those not in the stock may not enter this position but wait for new posts or go back to posts during the last 60 days  for additional ideas as well as look at the Model Portfolio.

Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007.  Please click here and scroll down to see the table of all trades.  These trades have been scrutinized in real-time by thousands of subscribers across the globe.  This provides easy verification of performance for newcomers to this site.  Only those trades are included in the performance where the entry post was made available to subscribers to The Arora Report Market Blog.  When the entry post is made available only to the paying subscribers and not posted in real-time on The Arora Report Market Blog, the resulting performance of the trade is not credited in the performance table.  There are very nice gains on this trade but since the entry trade was not posted here in real-time, handsome profits on this trade will not be added to the performance of The Arora Report Market Blog shown on the table.

You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE  30 day trial.

Check out our enviable performance in both bull and bear markets.

FREE: SUBSCRIBE TO ‘GENERATE WEALTH’ NEWSLETTER

Related Posts

TRUMP’S ‘OBAMACARE LITE’ PRESENTS OPPORTUNITIES AND PERILS FOR INVESTORS $XBI $MDT $BSX $EW $CYH $THC $PFE $JNJ $MRK $BMY $TEVA $MYL

Republicans have finally produced a detailed plan to repeal and replace the Affordable Care Act, also known as Obamacare. Setting aside ...

BUY ON TRUMP? SELL ON TRUMP? WHO IS RIGHT? $GOOGL $AAPL $FB $INTC $MSFT $NVDA $C $BAC $JPM $MRK

Donald Trump is starting his first full week as U.S. president. Bearish investors have been out in full force, proclaiming, ...

WHAT PHARMA INVESTORS OUGHT TO DO AFTER DONALD TRUMP FIRES A SALVO $LABD $PFE $JNJ $MRK $BMY $LLY $PJP $IHE $PPH $IBB $XHI $BBH $BIS

Donald Trump knocked yet another industry in his press conference Wednesday, but this time it wasn’t manufacturers or car makers. ...

FIVE UNPOPULAR, BUT PRUDENT, THINGS FOR INVESTORS TO DO NEAR DOW 20,000 $MLM $GIS $NVDA $SPY $AAPL $URI $MRK $JNJ $BMY $LLY $AVGO $INTC $ORCL

  I can safely say that, from my 35 years in the financial markets, to be consistently successful at investing, one ...

OUR POSITION ARIAD PHARMA GETS $24 BUYOUT OFFER, 237% RETURN FOR OUR SUBSCRIBERS $ARIA $ALIOY $TKPYY

This post was published on ZYX Buy Change Alert.  Original ARIA position is long from $7.11.  The buyout price represents 237% return.  If ...

OBAMACARE IS DEAD, WELCOME TRUMPCARE OPPORTUNITIES! $SPY $XLV $XHS $PJP $XBI $IHI $BMY $JNJ $PFE $MRK $ABT $ABBV $LLY $HUM $UNH $AET $ANTH $CI $HCE $CVH $THC $CNC $MOH

Democrats will fight tooth and nail to save Obamacare, but given the flaws in the plan, they are not likely ...

WEEKLY MARKET DIGEST: JAPAN STUNS WITH NEGATIVE INTEREST RATES, RUSSIA CLARIFIES ON OIL, FED REFUSES TO COW TAIL $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds ...

TAKE PROFITS ON SMITH & NEPHEW AND EXIT THE POSITION $SNN $MDT $SYK $COV $JNJ

One of the rumored suitors of  SNN has been MDT. MDT just bought COV and is now likely out of ...

INDIA COURT RULING AGAINST NOVARTIS IS DARK OMEN FOR BIG PHARMA $NVS $LLY $BMY $MRK $JNJ $PFE

It is official: India is siding with poor cancer patients over profits for multinational drug giants. The Supreme Court of India has rejected ...

WEEKLY MARKET DIGEST: THE RALLY IS LONG IN THE TOOTH $GLD $SLV $USO $DIA $SPY $QQQ $TBF $TBT $AAPL

(The Weekly Digest reproduces the morning capsules made available every morning before the market open in the Real Time Feeds ...

PATENT AWARD APPEALS HISTORY SUGGESTS APPLE MAY NOT GET ITS MONEY FROM SAMSUNG

Nine jurors in the Federal Court of the Northern District of California, handed Apple a big victory against Samsung, awarding Apple $1.05 ...

OBAMA OR ROMNEY, PHARMA IS A LOSER

A popular axiom among long-only investors is to “buy low sell high.” For those investors who are equally interested in making ...

$NUVA ( NUVASIVE ) PRESENTS A SHORT TERM TRADING OPPORTUNITY

NUVA stock has been down today on rumors that JNJ (Johnson & Johnson) will announce a lateral fusion device in ...

CONSIDER SHORTING MRK (MERCK)

Merck had the best two day gain ever in its history. After a 38% gain, this afternoon smart money was ...

Follow

Get every new post delivered to your Inbox

Join other followers